When ADHD medication stops working: the role of estrogen, the menstrual cycle, and perimenopause.

There is a clinical pattern common enough to warrant its own discussion.

A woman in her early 40s presents having been on a stable stimulant dose for years with good effect. Over the past 6 to 12 months, the medication has not been performing the same way. Afternoons become foggy. Tasks that were once manageable now feel effortful. She assumes tolerance has developed. Sometimes a provider has increased the dose, which helps briefly before fading again.

Then there is the mirror image. A 38-year-old who never needed ADHD treatment and never struggled academically is suddenly missing deadlines, losing her keys, and relying on sticky notes that are not keeping up. Her primary care provider referred her for an ADHD evaluation. When the conversation turns to her menstrual cycle and sleep, the clinical picture shifts.

Both patients may have ADHD. Both may also be in perimenopause. Often both are present simultaneously, and the reason stimulant medications feel unreliable comes down in large part to one hormone.

Estrogen does more than most clinicians appreciate

Estrogen is not solely a reproductive hormone. Estrogen receptors are distributed throughout the brain, including the prefrontal cortex, which governs attention, working memory, and impulse control. Estrogen also modulates dopamine neurotransmission: it increases dopamine receptor density and slows dopamine reuptake at the synapse. When estrogen levels are steady and adequate, the dopamine system operates efficiently. When estrogen drops, dopamine signaling weakens.

Recent preclinical data from a 2026 study published in the Journal of Clinical Investigation demonstrated this directly.¹ In female mice, dopamine release and clearance in the nucleus accumbens core were enhanced during high-estradiol phases of the estrous cycle. Amphetamine's potency was reduced by ovariectomy and restored by direct estradiol replacement in the nucleus accumbens core, while methylphenidate showed less hormone-sensitive regulation. Even within the stimulant class, different mechanisms of action appear to interact differently with estrogen-dependent dopamine function.

This matters clinically because every stimulant medication, including amphetamine, lisdexamfetamine, methylphenidate, and dexmethylphenidate, works by boosting dopamine activity. If baseline dopamine signaling is already compromised because estrogen is low, the same stimulant dose has less substrate to work with. The effect is subtle. It is not a total loss of medication response. Most women describe it as: "My medication still works, but it does not cut through the fog the way it used to."

Why the luteal phase is harder

A regular menstrual cycle has two halves. The follicular phase runs from menstruation through ovulation (approximately days 1 to 14), during which estrogen rises steadily. The luteal phase runs from ovulation to the next period (approximately days 15 to 28). During the luteal phase, progesterone climbs, estrogen falls relative to the first half of the cycle, and the hormonal ratio shifts in progesterone's favor.

Several converging factors make ADHD harder to manage in the second half of the cycle:

• Estrogen is lower, so dopaminergic support is diminished. Stimulant medications feel less effective at the same dose.
• Progesterone and its neuroactive metabolite allopregnanolone can worsen brain fog and flatten motivation in some women. A 2025 narrative review found that cognitive impairments in women with ADHD during the mid-luteal and premenstrual phases may reflect increased sensitivity to allopregnanolone and the absence of compensatory neural adaptations seen in non-clinical populations.⁴
• In the final 3 to 5 days before menstruation, both estrogen and progesterone drop sharply. This is the biological territory of PMS and PMDD.

A 2025 pilot study of 30 women treated with amphetamine salts for ADHD confirmed that ADHD symptom severity varied significantly by menstrual cycle phase, with symptoms most severe during menstruation and mildest during the mid-follicular phase.² A large cross-sectional survey of 600 women with ADHD found that 88.6% of premenopausal participants not taking hormonal therapy reported changes in ADHD symptoms across the menstrual cycle, with most reporting worsening during the luteal phase.³

For women with ADHD, this manifests as a reliable rhythm they often have not identified. Medication "works" for roughly two weeks per month. The other two weeks feel as though the stimulant is underdosed. Compensatory strategies like over-caffeinating and doubling up on tasks lead to exhaustion and frustration by the time menstruation arrives. Most women have never connected the two patterns until someone asks.

Perimenopause extends the difficult weeks across the entire month

Perimenopause is not a linear decline in estrogen. It is several years of hormonal instability. Estrogen surges and crashes unpredictably, and cycles shorten, lengthen, and skip. The luteal-phase dip that once affected two weeks per month begins to appear three weeks per month, then intermittently throughout the month.

A 2026 meta-analysis of 26 studies comprising 9,428 participants found that perimenopausal women exhibited poorer cognitive outcomes than premenopausal women, with a moderate effect size, though this was only significant in studies using standardized STRAW+10 criteria for reproductive staging.⁵

This is why so many women reach a clinical inflection point with ADHD in their late 30s and 40s. Those with an established regimen describe it as "my medication stopped working." Those without a prior diagnosis suddenly cannot manage work they previously handled with ease, and they present asking whether they have always had ADHD and missed it, or whether something new is happening.

Notably, a 2025 population-based cohort study found that women with ADHD have a significantly higher prevalence of severe perimenopausal symptoms compared to women without ADHD (54.2% vs. 30.1%), and that these symptoms present at an earlier age.⁶ That finding suggests an earlier onset of perimenopause in women with ADHD.

The honest answer is often: some of both.

Sorting out which is which

No single test cleanly separates these strands. But several patterns help guide the clinical picture.

Perimenopause is more likely a primary driver when:

• Focus and cognition were intact until the mid-to-late 30s or 40s, then shifted
• Symptoms worsen in the second half of the cycle, or the pattern has become unpredictable
• Sleep has changed (waking at 3 a.m. and remaining awake is a classic perimenopausal pattern)
• Hot flashes, night sweats, irregular periods, or new mood instability are also present
• A close female relative had early or difficult menopause

An ADHD evaluation (or revisiting an existing diagnosis) is warranted when:

• Focus difficulties have been present since childhood or adolescence, even if well-compensated
• There is a longstanding pattern of difficulty with time management, losing things, task initiation, and task completion
• Stimulant medication has historically been effective, and the question is whether it should still be
• There is a family history of ADHD or learning differences
• Symptoms are not confined to one part of the menstrual cycle

Both columns can be true simultaneously. That is not a diagnostic failure. It is the actual clinical picture for many women in midlife. A 2026 narrative review in Drugs & Aging emphasized that ADHD in women is frequently underdiagnosed and undertreated during midlife, precisely because the neuroendocrine changes of perimenopause can both exacerbate and unmask underlying ADHD symptoms, creating significant diagnostic overlap.⁷

What actually helps

The practical approach depends on the clinical picture.

If stimulant efficacy has declined and other perimenopausal symptoms are present, a trial of transdermal estradiol (with progesterone if the uterus is intact) may restore medication response without requiring a stimulant dose increase. Menopausal hormone therapy is not FDA-approved for ADHD treatment, and that distinction matters. However, the biology is consistent, the clinical pattern is consistent, and when the overall picture fits, it is a reasonable consideration.

If ADHD is newly identified or undertreated, starting or optimizing a stimulant is typically the appropriate first step. That process is paired with menstrual cycle tracking and a realistic conversation about which days are harder. A small 2023 case series of nine women with ADHD found that premenstrual elevation of psychostimulant dosage improved both ADHD and mood symptoms with minimal adverse events, and all nine women elected to continue the adjusted regimen over 6 to 24 months of follow-up.⁸ This approach remains preliminary and should be individualized. Comprehensive ADHD evaluations here include FDA-cleared QbTest objective measures, so decisions are not based on self-report alone.

If both conditions are in play, both should be treated. That is the entire rationale for having a comprehensive plan rather than cycling through partial solutions.

Sleep is also non-negotiable in this conversation. Poor sleep independently impairs executive function, and perimenopausal insomnia feeds cognitive symptoms directly. No stimulant can overcome a sleep debt.

ADHD and perimenopause care in Omaha, Papillion, and across Nebraska

At Midwest Mind & Body Healthcare, attention and hormones are evaluated together because, for many women in midlife, they are the same conversation. Kim Wohlwend, MSN, APRN, is dual ANCC board-certified as both a Family Nurse Practitioner and a Psychiatric-Mental Health Nurse Practitioner. That combination exists specifically for patients whose clinical picture does not fit neatly into one silo.

In-person at our Papillion office, by telehealth across Nebraska for mental-health visits, and across 16 states for hormone therapy.

References

1. Christensen BA, Tat J, Leonard MZ, et al. Sex and ovarian hormone cycles alter effects of stimulant drugs on mouse dopaminergic signaling. The Journal of Clinical Investigation. 2026.
2. Zaritsky R, Reed SC, Evans SM. Changes in ADHD symptoms and mood across the menstrual cycle in females treated with stimulants: a pilot study. Journal of Attention Disorders. 2025.
3. Osianlis E, Thomas EHX, Li Q, et al. ADHD in females: survey findings on symptoms across hormonal life stages. Journal of Psychiatric Research. 2025.
4. Wynchank D, Sutrisno RMGTMF, van Andel E, Kooij JJS. Menstrual cycle-related hormonal fluctuations in ADHD: effect on cognitive functioning — a narrative review. Journal of Clinical Medicine. 2025.
5. Bangle A, Williams D, Walters J, Nguyen L. Cognitive functioning in perimenopause: an updated systematic review and meta-analysis. Psychology and Aging. 2026.
6. Jakobsdóttir Smári U, Valdimarsdottir UA, Wynchank D, et al. Perimenopausal symptoms in women with and without ADHD: a population-based cohort study. European Psychiatry. 2025.
7. Wynchank D, Kooij S. Pharmacological management of ADHD in women across perimenopause, menopause and post-menopause. Drugs & Aging. 2026.
8. de Jong M, Wynchank DSMR, van Andel E, Beekman ATF, Kooij JJS. Female-specific pharmacotherapy in ADHD: premenstrual adjustment of psychostimulant dosage. Frontiers in Psychiatry. 2023.

This content is for educational purposes only and does not replace medical advice. Hormone therapy is not FDA-approved to treat ADHD. Treatment decisions are individualized and discussed during your visit.